Pyrotinib

Drug Profile

Pyrotinib

Alternative Names: BLTN; Pyrroltinib maleate

Latest Information Update: 06 Apr 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Shanghai Hengrui Pharmaceutical
  • Developer Jiangsu Hengrui Medicine Co.; Tongji University
  • Class Antineoplastics
  • Mechanism of Action Epidermal growth factor receptor antagonists; ERBB 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer; Non-small cell lung cancer
  • Phase I Gastric cancer

Most Recent Events

  • 17 Mar 2017 Jiangsu HengRui Medicine Co plans a phase III trial for Breast cancer(Metastatic disease, Combination therapy, Second-line therapy or greater) in China (NCT03080805)
  • 15 Dec 2016 Biomarkers information updated
  • 27 Sep 2016 Jiangsu HengRui Medicine initiates a phase II trial for Non-small cell lung cancer (Late-stage disease, Second-line therapy or greater) in China (PO) (NCT02834936)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top